Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai ChemPartner CEO Michael Hui On Finding A Niche In China Amidst Increasing Foreign Competition: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Shanghai ChemPartner was set up in 2003 at Shanghai's Zhangjiang Hi-Tech Park, and today it is one of the leading R&D outsourcing providers in China. PharmAsia News recently visited company headquarters to meet Michael Hui, CEO of ChemPartner - as well as sister company ChemExplorer, and their holding company ShangPharma - to discuss the company's recent deal with private equity investment firm TPG, as well as handling increased competition from foreign firms moving into China.

You may also be interested in...



Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang

It's about being a "sower and a grower" not a "seeker and a picker," Zhang said of Lilly's FIPNET philosophy.

Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang

It's about being a "sower and a grower" not a "seeker and a picker," Zhang said of Lilly's FIPNET philosophy.

Eli Lilly's China R&D Head Tony Zhang On Looking At The Universe Of Possibilities In China: An Interview With PharmAsia News

Eli Lilly was the first to coin the term FIPNET, which brings the focus of becoming a fully integrated pharmaceutical network on partnerships rather than doing it all as a fully integrated pharmaceutical company, or FIPCO. Eli Lilly's Head of China R&D Tony Zhang sat down with PharmAsia News along the sidelines of the recent Shanghai R&D Summit to discuss Lilly's approach to R&D in China. Much of doing R&D in China is about building up a local ecosystem for innovation and, according to Zhang, it is about being a "sower and a grower," rather than just a "seeker and a picker."

Related Content

Latest News
UsernamePublicRestriction

Register

SC068202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel